Pfizer reports favorable late-stage results for LITFULO in vitiligo
Pfizer reported favorable Phase 3 findings for LITFULO, also known as ritlecitinib, in nonsegmental vitiligo. The company said the oral treatment showed meaningful clinical benefit with an acceptable safety profile and plans regulatory applications in several markets, including the United States and Europe. LITFULO currently has authorization for severe alopecia areata, and Pfizer is pursuing vitiligo as an additional use.
Why it matters
A successful new indication could extend LITFULO's addressable dermatology market. Simply Wall St's analysis says Pfizer still needs to show that a vitiligo label can materially counter declining COVID-related revenue and upcoming patent losses.
Key facts
- 1Pfizer disclosed positive Phase 3 results for oral LITFULO in nonsegmental vitiligo. simplywall.st
- 2Pfizer said it intends to file for vitiligo approvals in multiple regions, including with U.S. and European regulators. simplywall.st
- 3LITFULO has existing approval for severe alopecia areata. simplywall.st
- 4The reported trial update described significant clinical benefit and a favorable safety profile. simplywall.st
Open questions
- The materials provide no efficacy measures, safety-event data, trial size, filing dates, or regulatory decision timeline.
- Regulatory authorization for vitiligo has not yet been granted.
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.